Physician profile
Kathi S Mccree
NPI 1497749816
$1,944.92
in general payments reported to CMS, 2019-2025
31 companies · $384 in 2025
The $384 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $181 · 2020: $142 · 2021: $291 · 2022: $301 · 2023: $380 · 2024: $265 · 2025: $384.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,030.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,030.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $370.90 | 2021-2025 | Farxiga, Breztri, Airsupra |
| Abbvie INC. | $308.01 | 2019-2024 | |
| Amgen INC. | $183.38 | 2021-2025 | Repatha, Otezla |
| Eisai INC. | $101.83 | 2020-2024 | |
| Antares Pharma, INC. | $98.98 | 2019-2025 | Xyosted, Tlando |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $97.57 | 2021-2025 | Xifaxan, Trulance |
| Pfizer INC. | $71.18 | 2022-2024 | |
| Verity Pharmaceuticals INC. | $52.35 | 2025 | Tlando |
| Lilly USA, LLC | $51.02 | 2022-2025 | Mounjaro |
| Acella Pharmaceuticals, LLC | $50.08 | 2024-2025 | NP Thyroid 60 |
| Otsuka America Pharmaceutical, INC. | $44.43 | 2025 | Rexulti |
| Tolmar, INC. | $44.02 | 2023-2024 | |
| Glaxosmithkline, LLC. | $43.31 | 2023 | Arexvy, Shingrix |
| Genentech USA, INC. | $42.23 | 2020-2021 | |
| Halozyme INC | $36.66 | 2023 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ibsa Pharma INC. | $34.66 | 2019 | |
| Optinose US, INC. | $34.02 | 2020 | |
| Medtronic, INC. | $33.96 | 2023 | Venaseal |
| Idorsia Pharmaceuticals US INC | $29.00 | 2023 | Quviviq |
| Janssen Pharmaceuticals, INC | $25.90 | 2019-2021 | |
| Acerus Pharmaceuticals Corporation | $24.01 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $23.66 | 2020 | |
| Biosense Webster, INC. | $22.79 | 2024 | Carto 3 |
| Hikma Pharmaceuticals USA | $18.52 | 2021 | |
| Melinta Therapeutics, LLC | $17.36 | 2019 | |
| Astellas Pharma US INC | $17.15 | 2023 | Veozah |
| Biohaven Pharmaceutical Holding Company LTD. | $16.64 | 2022 | |
| Exact Sciences Corporation | $14.94 | 2025 | Cologuard Collection Kit |
| Teva Pharmaceuticals USA, INC. | $13.02 | 2019 | |
| Arbor Pharmaceuticals, INC. | $11.99 | 2019 | |
| Merck Sharp & Dohme LLC | $11.35 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kathi Mccree listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.